文献速递脑血管病

半暗带再灌注对临床结局的影响取决于基线缺血核心体积

Influence of Penumbral Reperfusion on Clinical Outcome Depends on Baseline Ischemic Core Volume.
PubMed 文献 · Stroke · 2017-09-08

本研究纳入1507例接受阿替普酶治疗的急性缺血性卒中患者,分析24小时半暗带再灌注与90天临床结局的关系。校正基线缺血核心体积后,再灌注半暗带体积成为良好功能结局的强预测因子,每1%半暗带再灌注使90天mRS 0-1的 odds 增加7.4%,24小时NIHSS较基线下降0.069。

要点

  • 再灌注半暗带体积可预测90天良好功能结局,校正核心体积后预测力更强。
  • 每1%半暗带再灌注,90天mRS 0-1的 odds 增加7.4%。
  • 每1%半暗带再灌注,24小时NIHSS较基线下降0.069。

核心结论

  • 在接受阿替普酶治疗的患者中,再灌注的半暗带范围是早期和晚期临床结局的强预测因子,尤其当考虑基线缺血核心时。

研究设计与样本

  • 研究收集了7家医院发病4.5小时内就诊、具有基线和随访灌注成像的连续急性缺血性卒中患者数据。
  • 采用逻辑回归模型预测再灌注半暗带体积对90天二分法改良Rankin量表(mRS)和24小时美国国立卫生研究院卒中量表(NIHSS)改善的影响,并校正基线缺血核心体积。

主要发现

  • 研究共纳入1507例患者。
  • 再灌注半暗带体积对90天mRS 0-1有中等预测能力(曲线下面积0.77;R2 0.28;P<0.0001)。
  • 校正基线缺血核心体积后,再灌注半暗带体积是良好功能结局的强预测因子(曲线下面积0.946;R2 0.55;P<0.0001)。
  • 每1%半暗带再灌注增加,90天达到mRS 0-1的 odds 增加7.4%。
  • 24小时急性NIHSS改善也与再灌注半暗带程度显著相关(R2 0.31;P<0.0001),校正基线缺血核心体积后关联更强(R2 0.41;P<0.0001)。

临床怎么用

  • 在阿替普酶治疗的急性缺血性卒中患者中,评估再灌注半暗带体积有助于预测早期和晚期临床结局。
  • 考虑基线缺血核心体积可提高再灌注半暗带对临床结局的预测价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: In alteplase-treated patients with acute ischemic stroke, we investigated the relationship between penumbral reperfusion at 24 hours and clinical outcomes, with and without adjustment for baseline ischemic core volume. METHODS: Data were collected from consecutive acute ischemic stroke patients with baseline and follow-up perfusion imaging presenting to hospital within 4.5 hours of symptom onset at 7 hospitals. Logistic regression models were used for predicting the effect of the reperfused penumbral volume on the dichotomized modified Rankin Scale (mRS) at 90 days and improvement of National Institutes of Health Stroke Scale at 24 hours, both adjusted for baseline ischemic core volume. RESULTS: This study included 1507 patients. Reperfused penumbral volume had moderate ability to predict 90-day mRS 0 to 1 (area under the curve, 0.77; R2, 0.28; P<0.0001). However, after adjusting for baseline ischemic core volume, the reperfused penumbral volume was a strong predictor of good functional outcome (area under the curve, 0.946; R2, 0.55; P<0.0001). For every 1% increase in penumbral reperfusion, the odds of achieving mRS 0 to 1 at day 90 increased by 7.4%. Improvement in acute 24-hour National Institutes of Health Stroke Scale was also significantly related to the degree of reperfused penumbra (R2, 0.31; P<0.0001). This association was again stronger after adjustment for baseline ischemic core volume (R2, 0.41; P<0.0001). For each 1% of penumbra that was reperfused, the 24-hour National Institutes of Health Stroke Scale decreased by 0.069 compared with baseline. CONCLUSIONS: In patients treated with alteplase, the extent of the penumbra that is reperfused is a powerful predictor of early and late clinical outcomes, particularly when baseline ischemic core is taken into account.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Chen C, Parsons MW, Clapham M, et al. Influence of Penumbral Reperfusion on Clinical Outcome Depends on Baseline Ischemic Core Volume. Stroke. 2017. PMID: 28887396. doi:10.1161/STROKEAHA.117.018587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。